Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 10—October 2024
Research

Economic Analysis of National Program for Hepatitis C Elimination, Israel, 20231

Yuval DadonComments to Author , Francis B. Mimouni, Ariella Toren, Tal Morgenstern, Lior Barak, and Joseph Mendlovic
Author affiliations: Ministry of Health, Jerusalem, Israel (Y. Dadon, A. Toren, T. Morgenstern, L. Barak, J. Mendlovic); Leumit Health Care, Tel Aviv, Israel (F.B. Mimouni); Sackler School of Medicine, Tel Aviv (F.B. Mimouni); Shaare Zedek Medical Center, Hadassah-Hebrew University School of Medicine, Jerusalem (J. Mendlovic)

Main Article

Table 2

Cost estimation per a resolved HCV case in an economic analysis of a national program for hepatitis C elimination, Israel, 2023*

Category
 HCV antibody tested
Pending testing
 Program total cost
No. patients
 Cost per patient
 Total cost
 No. patients
 Cost per patient
 Total cost
Initial serology 555,083 23.5 13,044,451 308,826 23.5 7,257,411 20,301,862
PCR for positive serology
 24,361
 435.5
 10,609,216
13,588†
 435.5
 5,917,724
 16,526,939
Treatment 260,869,000‡
Posttreatment PCR for SVR 13,379 435.5 5,826,555 8,697§ 435.5 3,787,544 9,614,099
No. SVR patients
 12,911
 NA
 NA
8,392¶
 NA
 21,303
Total program cost
307,311,900
Cost per resolved HCV case 14,426 ($3,606)#

*A total of 863,909 persons were evaluated via serologic testing for HCV antibodies. Costs are in Israeli new shekel, except where indicated. HCV, hepatitis C virus; NA, not applicable; SVR, sustained viral response. †Given 4.4% positivity for HCV serology tested. ‡Overall treatment cost at Health Basket. §Given 64% positivity for HCV PCR testing. ¶Given 96.5% HCV resolution. #Conversion to US dollars based on 2012 data from ExchangeRates.org (https://www.exchangerates.org). Data should be inflation adjusted for accumulated inflation during 1999–2021.

Main Article

1Preliminary results from this study were presented at the Israel National Institute for Health Policy Research conference; May 31, 2023; Tel Aviv, Israel.

Page created: August 21, 2024
Page updated: September 23, 2024
Page reviewed: September 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external